newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - CRINETICS PHARMACEUTICALS INC

  • Explicit Guidance:

    • No specific quantitative financial guidance (revenue, earnings, margins, or capex) provided for FY2026 or FY2027.
    • Non-CF revenue outlook: Targeting >$500 million from non-CF products in 2026; expecting revenue to exceed this threshold in 2027 following the acquisition of Krenetics and the addition of Gernavix and Casgevi.
    • Pipeline timing targets:
      • November 30, 2026: PDUFA decision for povitacicept (IgAN).
      • Early 2027 (Q1): Interim analysis data for anaxiplin (Amplitude study in APOL1-MKD); Phase 3 proof-of-concept data for povitacicept (Myasthenia Gravis).
      • Mid-2027: Data expected from two Phase 3 studies for suzetrogene (Diabetic Peripheral Neuropathy).
      • Late 2027/Early 2028: Data readout expected for atumelanin (Krenetics acquisition) after Q1 2027 enrollment completion.
  • Business-Segment Outlook:

    • Renal Franchise:
      • Povtitacicept (IgAN): Positioned as third-to-market; confidence in US uptake despite lack of two-year eGFR data at launch, citing consistent proteinuria reduction across North American subgroups.
      • Anaxiplin (APOL1-MKD): Confidence in hitting eGFR slope endpoint for accelerated approval at Q1 2027 interim analysis; target includes all comers with APOL1 variants (FSGS or otherwise), potentially 50% larger population if comorbidities like Type 2 Diabetes are included (totaling ~250k US patients vs. 160k IgAN).
      • Suzetrogene: First Phase 3 programs in peripheral/chronic pain; expected data mid-2027.
      • Expansion: Pipeline includes Primary Membranous Nephropathy (Phase 3), Autosomal Dominant Polycystic Kidney Disease (ADPKD), and Myasthenia Gravis.
    • Cystic Fibrosis (CF): Solid outlook expected despite diversification efforts; CF franchise remains a cash flow driver.
    • Commercial Infrastructure: Plans to deploy the largest field force in disease-modifying renal agents; will replicate the 80% usage patient services model (live support, reimbursement navigation) from CF to renal.
  • Market and Competitive Outlook:

    • Pricing and Reimbursement: Anticipating a "Maximum Fair Price" (MFN)-aware environment; leveraging partnerships (Ono Pharma in Japan, Zai Lab in China) to manage global pricing flexibility and preserve US pricing power.
    • Competitive Landscape:
      • IgAN: Competitors show varying efficacy in hematuria resolution and proteinuria reduction; Vertex differentiates via faster reduction rates and lower-dosing convenience (4-week autoinjector vs. weekly or higher-dose peers).
      • APOL1-MKD: Aiming to educate physicians on genotyping (Black and Hispanic populations) to identify the undiagnosed patient pool; positioning as the first precision genetic medicine for kidney disease.
    • Market Expansion: View Asia as the largest patient opportunity (1.5M–1.6M globally) compared to the ~330k biopsy-confirmed population in the US/Europe.
  • Macro / Industry Outlook:

    • Regulatory Environment:
      • US path is accelerated approval based on proteinuria/eGFR slope; global markets (Europe, Asia) require firm two-year eGFR endpoints.
      • Confidence in avoiding IgG monitoring requirements on the label, citing low infection risk (0.5% in interim data) consistent with the placebo arm.
    • Healthcare Policy: Acknowledges political neutrality regarding MFN policies; expects equitable healthcare expenditure discussions to persist regardless of US election outcomes.
    • Economic Factors: Management does not comment on FX rates, interest rates, or inflation impacts on short-term guidance.
  • Strategic Initiatives:

    • Krenetics Acquisition: Completed to access atumelanin for Chronic Hepatitis B; fits strategy of severe disease with known biology.
    • Capacity/Manufacturing: High confidence in meeting PDUFA cadence and manufacturing output for povitacicept; inspections and priority review schedule are "on track."
    • Partnerships: Existing commercial partnerships with Ono Pharma (Japan/Asia) and Zai Lab (China); collaboration with Alonzo Mourning for community outreach regarding APOL1 genotyping.
    • Pipeline Advancement: Accelerating enrollment and readouts for APOL1-MKD (Amplitude) and Myotonic Dystrophy Type 1 (Phase 2 data by year-end).
  • Risks and Headwinds to Outlook:

    • Regulatory Risk: Failure to meet two-year eGFR endpoints in global markets could limit approval outside the US; reliance on accelerated approval in the US carries long-term confirmation data requirements.
    • Clinical/Development Risk: Atumelanin liver safety signal observed in Phase 2 (one event, resolved); ongoing Phase 2 open-label extension and Q1 2027 enrollment completion for Phase 3 are critical.
    • Market Adoption: Potential challenges in uptake due to the need for physician education on APOL1 genotyping and the "switching market" for IgAN patients currently on competitor therapies.
    • Competition: Two competitors already launched in IgAN; need to differentiate on efficacy consistency and ease of administration to gain share.
  • Management Tone on the Future:

    • High Confidence: Management expresses strong conviction regarding povitacicept efficacy (best-in-class potential), manufacturing readiness, and regulatory labeling (no IgG monitoring).
    • Optimistic on Catalysts: Describes 2027 as "the most impactful year" for diversification away from CF, driven by potential accelerated approvals for povitacicept, anaxiplin, and suzetrogene.
    • Strategic Aggressiveness: Viewed as "being on the offensive" via the Krenetics acquisition; willingness to take risks on unique patient populations (APOL1 variants) and aggressive commercial messaging.
    • Transparency: Explicitly avoids hedging on the PDUFA date and manufacturing capability; clearly distinguishes their view on long-term safety vs. competitor data.
  • Miscellaneous:

    • PDUFA Label Specifics: Firm belief that the label will be consistent with the class, lacking IgG monitoring requirements, based on interim infection safety data.
    • Enrollment Metrics: Amplitude study included ~200 patients in the interim analysis; enrollment concluded successfully after a "very long time" due to global genotyping efforts.
    • Investment Thesis: 2026 focused on catalysts and launches; 2027 focused on data readouts driving potential accelerated approvals across multiple renal indications.
Company
CRINETICS PHARMACEUTICALS INC
Keywords
CRINETICS PHARMACEUTICALS INC